Monday, October 21, 2013

Reuters: Global Markets: Actelion hits six-year high after favorable FDA approval for drug

Reuters: Global Markets
Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals. // via fulltextrssfeed.com 
Manage your social media

Best social media tool for image publishing to Facebook and Twitter. Look amazing and delight your followers. Get 40% off when you sign up today.
From our sponsors
Actelion hits six-year high after favorable FDA approval for drug
Oct 21st 2013, 08:55

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel, April 23, 2011. REUTERS/Christian Hartmann

A general view shows Swiss biotech group Actelion Headquarters in Allschwil near Basel, April 23, 2011.

Credit: Reuters/Christian Hartmann

ZURICH | Mon Oct 21, 2013 4:55am EDT

ZURICH (Reuters) - Shares in Swiss group Actelion climbed more than five percent to their highest since late 2007 on Monday on optimism it has a viable product to secure sales and profit after U.S. approval for a new heart and lung drug with a favorable label.

The Food and Drug Administration approved the Swiss biotech company's pulmonary arterial hypertension (PAH) drug Opsumit late on Friday and, notably, did not impose a black box warning requiring ongoing mandatory liver testing.

This gives the medicine an advantage over Actelion's older product and current main seller, Tracleer, which had sales of 1.5 billion Swiss francs ($1.66 billion) in 2012 but loses patent protection from 2015.

"Opsumit's FDA approved label is close to a best case outcome, in our view," said Deutsche Bank analyst Richard Parkes, who has a 'buy' rating on the stock and raised his price target to 72 francs from 70 francs.

Shares in Actelion were up 5.3 percent at 68.00 francs by 0752 GMT, outperforming a 0.5 percent firmer European healthcare sector index.

Analysts at Jefferies agreed and said the drug had the "unique indications" of delaying disease progression and reducing hospitalization due to PAH.

The brokerage, which forecasts peak sales of $1.4 billion assuming a 40 percent new PAH patient share at a 15 percent price discount to Tracleer and Gilead Sciences' rival drug Letairis, also raised its price target to 79 francs from 71 francs.

Analysts at Berenberg were more cautious and said the requirement for doctors to carry out pre-therapy liver testing before prescribing Opsumit was slightly more burdensome than what is required for Letairis.

Pulmonary arterial hypertension, or PAH, is characterized by high blood pressure in the arteries connecting the heart to the lungs, which causes the right side of the heart to work harder than normal and leads to shortness of breath.

Opsumit belongs to a class of drugs known as endothelin receptor antagonists, which relax the pulmonary arteries and decrease that pressure.

($1 = 0.9017 Swiss francs)

(Reporting by Caroline Copley, Editing by Patrick Lannin)

  • Tweet this
  • Link this
  • Share this
  • Digg this
  • Email
  • Reprints

Comments (0)

Be the first to comment on reuters.com.

Add yours using the box above.


You are receiving this email because you subscribed to this feed at blogtrottr.com.

If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions

0 comments:

Post a Comment

 
Great HTML Templates from easytemplates.com.